Aurobindo Pharma マネジメント
マネジメント 基準チェック /34
Aurobindo Pharmaの CEO はKambam Reddyで、 Jun2006年に任命され、 の在任期間は 18.42年です。 の年間総報酬は₹ 45.05Mで、 50.9%給与と49.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の5.61%を直接所有しており、その価値は₹ 40.28B 。経営陣と取締役会の平均在任期間はそれぞれ9.5年と5.5年です。
主要情報
Kambam Reddy
最高経営責任者
₹45.0m
報酬総額
| CEO給与比率 | 50.9% |
| CEO在任期間 | 18.4yrs |
| CEOの所有権 | 5.6% |
| 経営陣の平均在職期間 | 9.5yrs |
| 取締役会の平均在任期間 | 5.5yrs |
経営陣の近況
Recent updates
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
Nov 12
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price
Oct 20Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Sep 10This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹36b |
| Jun 30 2024 | n/a | n/a | ₹35b |
| Mar 31 2024 | ₹45m | ₹23m | ₹32b |
| Dec 31 2023 | n/a | n/a | ₹28b |
| Sep 30 2023 | n/a | n/a | ₹23b |
| Jun 30 2023 | n/a | n/a | ₹20b |
| Mar 31 2023 | ₹37m | ₹19m | ₹19b |
| Dec 31 2022 | n/a | n/a | ₹20b |
| Sep 30 2022 | n/a | n/a | ₹21b |
| Jun 30 2022 | n/a | n/a | ₹24b |
| Mar 31 2022 | ₹27m | ₹14m | ₹26b |
| Dec 31 2021 | n/a | n/a | ₹29b |
| Sep 30 2021 | n/a | n/a | ₹52b |
| Jun 30 2021 | n/a | n/a | ₹53b |
| Mar 31 2021 | ₹23m | ₹20m | ₹53b |
| Dec 31 2020 | n/a | n/a | ₹54b |
| Sep 30 2020 | n/a | n/a | ₹31b |
| Jun 30 2020 | n/a | n/a | ₹30b |
| Mar 31 2020 | ₹15m | ₹13m | ₹28b |
| Dec 31 2019 | n/a | n/a | ₹26b |
| Sep 30 2019 | n/a | n/a | ₹26b |
| Jun 30 2019 | n/a | n/a | ₹25b |
| Mar 31 2019 | ₹15m | ₹13m | ₹24b |
| Dec 31 2018 | n/a | n/a | ₹23b |
| Sep 30 2018 | n/a | n/a | ₹22b |
| Jun 30 2018 | n/a | n/a | ₹24b |
| Mar 31 2018 | ₹15m | ₹13m | ₹24b |
報酬と市場: Kambamの 総報酬 ($USD 533.60K ) は、 Indian市場 ($USD 776.13K ) の同様の規模の企業の平均を下回っています。
報酬と収益: Kambamの報酬は過去 1 年間で 20% 以上増加しました。
CEO（最高経営責任者
Kambam Reddy (66 yo)
18.4yrs
在職期間
₹45,048,542
報酬
Mr. Kambam Nithyananda Reddy has been Vice Chairman of Aurobindo Pharma Limited since June 1, 2012 and serves as a Whole Time Director of Aurobindo Pharma Limited since December 26, 1986 and serves as Mana...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Vice Chairman & MD | 18.4yrs | ₹45.05m | 5.61% ₹ 40.3b | |
| Whole-Time Director | no data | ₹60.15m | データなし | |
| President of Biologics | 8.8yrs | ₹300.00k | データなし | |
| Chief Financial Officer | 10.3yrs | ₹21.06m | データなし | |
| President of Technical | no data | データなし | データなし | |
| Compliance Officer & Company Secretary | 8.4yrs | ₹4.76m | データなし | |
| Senior Vice President of Global Finance & Operations | no data | データなし | データなし | |
| Head of Global Finance Operations | no data | データなし | データなし | |
| Chief Quality Officer -Corporate QA | no data | データなし | 0.025% ₹ 176.7m | |
| President of Chemical Research | no data | データなし | データなし | |
| President of RAD-II | no data | ₹9.14m | データなし | |
| President-ARD | no data | ₹10.09m | データなし |
9.5yrs
平均在職期間
60yo
平均年齢
経験豊富な経営陣: AUROPHARMAの経営陣は経験豊富で経験豊富です（平均在職期間は9.5年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Vice Chairman & MD | 37.9yrs | ₹45.05m | 5.61% ₹ 40.3b | |
| Whole-Time Director | 18.2yrs | ₹60.15m | データなし | |
| President of Biologics | less than a year | ₹300.00k | データなし | |
| Non-Executive Director | 37.9yrs | ₹600.00k | 3.07% ₹ 22.0b | |
| Non-Executive Director | 17.2yrs | ₹900.00k | データなし | |
| Independent Director | 1.8yrs | ₹2.50m | データなし | |
| Independent Director | no data | ₹500.00k | データなし | |
| Additional Non-Executive Independent Director | 6.9yrs | ₹2.20m | データなし | |
| Independent Director of Apitoria Pharma Private Limited | 1.6yrs | データなし | データなし | |
| Independent Non-Executive Chairman | less than a year | データなし | データなし | |
| Non-Executive Independent Director | 4yrs | ₹2.60m | データなし |
5.5yrs
平均在職期間
64yo
平均年齢
経験豊富なボード: AUROPHARMAの 取締役会 は 経験豊富 であると考えられます ( 5.5年の平均在任期間)。